Home

Sriram Ryali

CIK 1762893 · Chief Financial Officer · last filed 2026-02-20

Sriram Ryali is a Chief Financial Officer who has filed 15 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for CRBU, was dated Feb 20, 2026. Across all open-market trades the lifetime net is +$45.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $335.9K across reported positions. 4 SEC filings were submitted jointly with Caribou Biosciences, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$335.9K

Companies

3

Total Filings

15

Lifetime Open-Market Net

$45.7K

Filer Profile

Reported Address
C/O EIGER BIOPHARMACEUTICALS, INC.
2155 PARK BLVD.
PALO ALTO, CA 94306
Related Filers
Caribou Biosciences, Inc. — 4 joint filings, latest 2026-02-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRBU Chief Financial Officer 72,360 $1.29 $93.3K $24.7K 3 2026-02-20
CDXS Chief Financial Officer 175,791 $1.38 $242.6K $19.9K 3 2024-01-02
Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Chief Financial Officer 1,386 $1.73 $2.4K $1.2K 9 2022-03-14

Recent Filings

15 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-20 CRBU Grant (A) +55,000 $0 EDGAR
2025-01-30 CRBU Buy (P) +17,360 $24.7K EDGAR
2025-01-10 CRBU Grant (A) — $0 EDGAR
2024-01-02 CDXS Grant (A) +52,350 $0 EDGAR
2023-09-12 CDXS Buy (P) +11,650 $19.9K EDGAR
2023-02-14 CDXS Grant (A) +111,791 $0 EDGAR
2022-03-14 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Sell (S) −2,266 -$12.7K EDGAR
2022-03-11 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Grant (A) +24,000 $0 EDGAR
2021-07-30 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Grant (A) — $0 EDGAR
2021-05-11 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 15
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.